Imperiale M J, Pass H I, Sanda M G
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor 48109-0942, USA.
Semin Cancer Biol. 2001 Feb;11(1):81-5. doi: 10.1006/scbi.2000.0349.
The identification of SV40 as a possible cause of human cancer leads to the question of whether the unique properties of the virus can be exploited to treat patients with SV40-positive mesotheliomas, which are otherwise refractory to successful intervention. A modified SV40 T antigen, from which the transforming domains have been removed, has been cloned into a vaccinia virus vector and tested in animal tumor model systems. It has been shown to be effective against both subsequent tumor challenge and pre-existing tumors. Thus, the potential exists for use of such a vaccine in mesothelioma patients.
